Early Detection,
Better Outcomes.

Guided Therapeutics, Inc. (OTC: QB GTHP) is committed to developing groundbreaking medical devices using our patented biophotonic technology to detect diseases earlier, more accurately, and more efficiently than other tests.


Product Information

Our products are designed to improve the patient’s experience, provide the physician with more powerful tools, improve the efficiency of the healthcare system and increase shareholder value.

How we are making
a difference globally

We are the maker of rapid and painless testing platform. The LuViva uses artificial intelligence (AI) to identify the key spectral components diagnostic of developing cancer.

Our products are designed to:


Improve the patient’s experience.


Provide the physician with more powerful tools.


Improve the efficiency of the healthcare system.


Our patented technology, which features our flagship product the LuViva® Advanced Cervical Scan, uses biophotonics to detect both physical and chemical changes in tissues that are early signs of cancer.



Cancer screening is a compelling market opportunity proven to save lives. As a pioneering company in this space, GTI represents an excellent investment.

Join our network of Investors

We are actively seeking new investors to join our network. We provide full transparency into our organization and would love to have you join.


We’re international and expanding. Read about Guided Therapeutics

Recent Press Releases

Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites with Better Than Expected Results

July 10, 2024

Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results

February 20. 2024

GTI Provides Update on Start of Clinical Trial for US FDA Approval

May 01, 2023

GTI Signs Agreement to Begin Clinical Trial for US FDA Approval

Dec 23, 2022